Search research articles
Contact Us
Filters
Showing results (51-60 of 122) with videos related to
Page
of 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2013
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial
Athanassios Argiris, Musie Ghebremichael, Jill Gilbert, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 6, 2007
Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story
Athanassios Argiris, Thomas Hensing, Anjana Yeldandi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2011
Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer
Athanassios Argiris, Michalis V Karamouzis, William E Gooding, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 12, 2024
A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305
Athanassios Argiris, Yael Flamand, Panayiotis Savvides, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2011
Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab
Neil E Bhola, Sufi M Thomas, Maria Freilino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Growth and molecular interactions between tamoxifen and trastuzumab
Alejandro Vázquez-Martín, Ramon Colomer, Santiago Ropero, et al.
Anticancer Research
|
October 15, 2013
Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer
Ahmad A Tarhini, Haris Zahoor, Brian McLaughlin, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 25, 2003
Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review
Bharat B Mittal, Barbara R Pauloski, Daniel J Haraf, et al.
Cancer Biology & Therapy
|
March 19, 2003
Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer
Eric Bleickardt, Athanassios Argiris, Randy Rich, et al.
Head & Neck
|
July 14, 2012
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group
Jill Gilbert, Ju Whei Lee, Athanassios Argiris, et al.
Page
of 13
Search research articles
Search
Showing results (51-60 of 122) with videos related to
Sort By:
Page
of 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2013
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial
Athanassios Argiris, Musie Ghebremichael, Jill Gilbert, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 6, 2007
Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story
Athanassios Argiris, Thomas Hensing, Anjana Yeldandi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2011
Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer
Athanassios Argiris, Michalis V Karamouzis, William E Gooding, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 12, 2024
A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305
Athanassios Argiris, Yael Flamand, Panayiotis Savvides, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2011
Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab
Neil E Bhola, Sufi M Thomas, Maria Freilino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Growth and molecular interactions between tamoxifen and trastuzumab
Alejandro Vázquez-Martín, Ramon Colomer, Santiago Ropero, et al.
Anticancer Research
|
October 15, 2013
Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer
Ahmad A Tarhini, Haris Zahoor, Brian McLaughlin, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 25, 2003
Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review
Bharat B Mittal, Barbara R Pauloski, Daniel J Haraf, et al.
Cancer Biology & Therapy
|
March 19, 2003
Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer
Eric Bleickardt, Athanassios Argiris, Randy Rich, et al.
Head & Neck
|
July 14, 2012
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group
Jill Gilbert, Ju Whei Lee, Athanassios Argiris, et al.
Page
of 13